Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

CIBC World Lowers 'Guidant' to 'Sector Underperform'

CIBC World downgraded Guidant (GDT) to sector underperform.

A U.S. District Court reportedly ruled in favor of Boston Scientific's drug-coated stent patent dispute with Cook and Guidant. Analyst John Calcagnini says the court decided to enjoin Guidant's paclitaxel-coated stent data from its Deliver trial. While Guidant can appeal, the case doesn't look good for Guidant. He notes Guidant could attempt to negotiate with Boston Scientific for paclitaxel rights or negotiate with Johnson & Johnson for a way to commercialize J&J's rapamycin, but it's hard to see what Guidant could offer these companies, barring a sizeable cash payment that would wipe out future profits from drug-eluting stents.

Calcagnini cut the $2.30 2003 earnings per share estimate to $2.14.

blog comments powered by Disqus